Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 14.7% compared with 2.8% growth of the industry. The S&P 500 Composite has risen 22.5% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing dr ...

Cencora (COR) shares soared 3.7% in the last trading session to close at $233.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.8% loss over the past four weeks. Cencora recorded a strong price rise driven by investors' optimism surrounding the company's upcoming earnings release, scheduled on Nov. 6, 2024. The Zacks Consensus Estimate for the fiscal fourth quarter suggests a revenue growth of 12.7% and earnings growth of 12. ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Cencora (COR) , which belongs to the Zacks Medical Services industry. This prescription drug distributor has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 4.57%. For the most recent quarter, Cencora was expected to post earnings of $ ...

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 10.3% year to date compared with the industry's 7.4% growth. The S&P 500 Index has risen 17.7% in the same time frame. Cencora is one of the world's largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve ...

Core Viewpoint - Cencora reported strong Q3 fiscal 2024 earnings, beating estimates and raising guidance for the fiscal year, despite a recent decline in share price [2][9][10]. Financial Performance - Adjusted earnings per share (EPS) for Q3 2024 was $3.34, exceeding the Zacks Consensus Estimate of $3.18 by 5% and showing a year-over-year increase of 14.4% [2]. - Total revenues reached $74.2 billion, reflecting a 10.9% year-over-year growth and surpassing the Zacks Consensus Estimate by 0.8% [3]. - U.S. Healthcare Solutions segment revenues were $67.2 billion, up 12.2% year-over-year, driven by high demand for GLP-1 drugs [3]. Segment Analysis - Segmental operating income was $698.3 million, a 9.9% increase year-over-year, supported by higher gross profit from COVID-19 treatment distribution [4]. - International Healthcare Solutions segment revenues remained flat at $7.1 billion year-over-year, but increased by 5.8% at constant currency [4]. - Operating income for the International segment was $179.4 million, down 4.1% but up 0.8% at constant currency, impacted by higher IT expenses [5]. Margin Analysis - Gross profit was $2.4 billion, a 6.5% increase year-over-year, with a gross margin of 3.25%, down 13 basis points from the previous year [6]. - Operating income was $672.5 million, flat year-over-year, with an operating margin of 0.91%, contracting 9 basis points [6]. Financial Position - Cencora ended Q3 with cash and cash equivalents of $3.31 billion, up from $2.29 billion in the prior quarter [7]. - Cumulative net cash used in operating activities was $2.48 billion, compared to $2.08 billion a year ago [7]. Dividend Update - The board declared a quarterly dividend of 51 cents per share, payable on August 26, 2024, to shareholders of record on August 9, 2024 [8]. Guidance Update - The company raised its fiscal 2024 adjusted EPS outlook to $13.55-$13.65, indicating a growth of 13-13.8% year-over-year [9]. - Revenue growth is now projected at 12%, up from previous guidance of 10-12%, with U.S. Healthcare Solutions expected to grow 12-13% [10]. - Adjusted operating income is anticipated to improve by 10-11%, with U.S. Healthcare Solutions projected to grow 11-12% [11]. Market Position - Cencora has a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [14]. - The stock has a strong aggregate VGM Score of A, reflecting good growth potential and value [13].

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 16.6% compared with 6% growth of the industry. The S&P 500 Composite has risen 17.5% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing drug ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed alo ...

Cencora (COR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Since a chan ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 ... [+] billion, which will be used "primarily for debt paydown and general corporate purposes," the drugstore giant said August 1, 2024 In this photo, a business sign hangs over the entrance to a Walgreens pharmacy and store in Alexandria, Virginia. (Photo by Robert Alexander/Getty Images) Getty Images Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 billi ...